Safety Profile of RINVOQ™ (upadacitinib): Analysis of Up to ~3.5 Years of Exposure in Patients With Rheumatoid Arthritis
Sponsored by AbbVie Medical Affairs
Jul 01, 2020
Autoimmune/Lupus
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include:
SELECT-CHOICE study. ABA vs. UPA in…
Autoinflammatory/Still's Disease Panel - EULAR2020
Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Long Delays in Denosumab Increase Fracture Risk (SAT0453). A UK population based study looked at risk of fracture in adults…
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Voclosporin Effective in Lupus Nephritis (OP0277). Voclosporin is a calcineurin inhibitor that has performed well in an earlier…
For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf. Listed…
Flares in ANCA-associated vasculitis are difficult to predict, but serum calprotectin may help predict relapse and renal failure, according to data presented at the EULAR 2020 virtual meeting this…
These were my top abstracts from Thursday, 4th of June at EULAR 2020.
TORTUGA Study (THU0377): Filgotinib in active axial spondyloarthritis patients. TORTUGA enrolled 116 patients with AxSpA.…
Lupus Management at EULAR 2020
Dr. Kathryn Dao highlights SLE presentations from virtual EULAR 2020 meeting June 3-6, 2020
- HCQ levels predicts VTE
- Can you withdraw MMF in stable SLE patients?
-Updated EULAR Lupus Treatment guidelines
Janet Pope Janetbirdope
1 month ago
Can you classify SLE by labs only but should you? Serology is part of criteria but why dx with only +ANA, +antiDNA and no other CTD characteristics. Would need cytopenias & RBC casts to think of lab dx of SLE OP0094 @LupusCanada @RheumNow @eular_org #EULAR2020 @CRASCRRheum https://t.co/Jr6SRr3HR1
Therapeutic Update
Presented here is an update on the longer-term safety profile of upadacitinib, drawing on the integrated analysis of up to ~3.5 years of exposure data from five Phase 3 studies. Dr. Winthrop and Dr. Cush provide additional information from relevant EULAR 2020 posters.
Read Post
